FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

JRITIES AND EXCHANGE COMMUNISSION

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Marriott Tina	ess of Reporting Pe	rson* (Middle)	2. Issuer Name and Ticker or Trading Symbol RECURSION PHARMACEUTICALS, INC. [RXRX]		tionship of Reporting Pers all applicable) Director Officer (give title below)	son(s) to Issuer 10% Owner Other (specify below)	
41 S. RIO GRA	` '	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 08/29/2024	President and	President and COO		
,			06/27/2024				
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	idual or Joint/Group Filing	g (Check Applicable	
	UT	84101		1	Form filed by One Repo	· ·	
					Form filed by More than Person	1 One Reporting	
(City)	(State)	(Zip)					
		Table I - Non-Deriva	ative Securities Acquired. Disposed of, or Benefi	cially	Owned		

rabio : rion borrativo documento rioquirou, bioposcou oi, oi borionolariy o micu											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed 3. Execution Date, if any (Month/Day/Year) 8)						5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Class A Common Stock	08/29/2024		M ⁽¹⁾		6,000	A	\$1.06	527,138	D		
Class A Common Stock	08/29/2024		S ⁽¹⁾		6,000	D	\$7.5627(2)	521,138	D		
Table II. Desirative Consulting Assuring Biomagnet of an Bourficially Council											

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Seco Acq (A) o Disp of (E	osed 0) tr. 3, 4	6. Date Exerc Expiration Da (Month/Day/\)	Date Amoun' (Year) Securiti Underly Derivati		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$1.06	08/29/2024		M ⁽¹⁾			6,000	(3)	07/22/2028	Class A Common Stock	6,000	\$0	464,000	D	
Stock Option (Right to Buy)	\$8.55							(4)	02/01/2033	Class A Common Stock	0		434,122	D	
Stock Option (Right to Buy)	\$11.4							(5)	02/04/2032	Class A Common Stock	0		159,226	D	
Stock Option (Right to Buy)	\$11.4							02/04/2022	02/04/2032	Class A Common Stock	0		4,784	D	
Stock Option (Right to Buy)	\$2.48							(6)	12/30/2030	Class A Common Stock	0		150,000	D	
Stock Option (Right to Buy)	\$10.09							(7)	02/09/2034	Class A Common Stock	0		447,917	D	

Explanation of Responses:

- 1. Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024.
- 2. This transaction was executed in multiple trades at prices ranging from \$7.34 to \$7.77 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- 3. Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
- 4. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
- 5. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
- 6. One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.

7. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

Remarks:

/s/Jonathan Golightly, attorneyin-fact 09/03/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.